View | NM_001110792.2(MECP2):c.1A>T (p.Met1Leu) | Likely Pathogenic | Rett syndrome | 2024-12-20 | 2.3 | ClinGen Rett and Angelman-like Disorders Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for MECP2 Version 3.0.0 | MECP2 |
View | NM_001110792.2(MECP2):c.1A>T (p.Met1Leu) | Likely Pathogenic | Rett syndrome | 2024-12-20 | 2.2 | ClinGen Rett and Angelman-like Disorders Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for MECP2 Version 3.0.0 | MECP2 |
View | NM_001110792.2(MECP2):c.1A>T (p.Met1Leu) | Likely Pathogenic | Rett syndrome | 2024-11-29 | 2.1 | ClinGen Rett and Angelman-like Disorders Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for MECP2 Version 3.0.0 | MECP2 |
View | NM_001110792.2(MECP2):c.1A>T (p.Met1Leu) | Likely Pathogenic | Rett syndrome | 2024-11-29 | 2.0 | - | MECP2 |
View | NM_001110792.2(MECP2):c.1A>T (p.Met1Leu) | Likely Pathogenic | Rett syndrome | 2021-12-27 | 1.0 | - | MECP2 |